•
Dec 31, 2022

biote Q4 2022 Earnings Report

Biote achieved record financial results driven by strong growth in revenue and Adjusted EBITDA.

Key Takeaways

Biote reported a strong fourth quarter and full year 2022, with revenue reaching $44.5 million, an 18.5% increase year over year, and net income of $12.8 million, or $0.18 per diluted share. The company's Adjusted EBITDA increased by 40% to $13.1 million. For the full year, revenue was $165.0 million, and Adjusted EBITDA was $50.1 million.

Revenue for the fourth quarter of 2022 was $44.5 million, an 18.5% increase from $37.5 million for the fourth quarter of 2021.

Net income for the fourth quarter of 2022 was $12.8 million, or $0.18 per diluted share, compared to net income of $5.5 million for the fourth quarter of 2021.

Adjusted EBITDA for the fourth quarter of 2022 was $13.1 million compared to $9.4 million for the fourth quarter of 2021, a 40% increase.

Gross profit margin for the fourth quarter of 2022 was 65.3% compared to 64.0% for the fourth quarter of 2021.

Total Revenue
$44.5M
Previous year: $37.5M
+18.5%
EPS
$0.18
Previous year: $0.724
-75.1%
Gross Profit
$29.1M
Previous year: $24M
+21.0%
Cash and Equivalents
$79.2M
Free Cash Flow
$6.05M
Total Assets
$112M

biote

biote

Forward Guidance

Biote anticipates continued growth in both revenue and Adjusted EBITDA in 2023, with stronger performance expected in the second half of the year.

Positive Outlook

  • Continued growth in revenue
  • Continued growth in Adjusted EBITDA
  • Further build market presence
  • Further build practitioner network
  • Benefit from the contributions of sales personnel added at the end of last year